| Literature DB >> 31466608 |
J Wade Atkins1, Kamille West2, Kimberly A Kasow3.
Abstract
Cell biology researchers, cellular engineers, and clinicians are teaming together to create powerful drugs. The use of cell-derived products as biologics is rapidly advancing. These human cell-based products have great potential for treating serious conditions but may have unidentified risks. Manipulations, expansions, and gene modifications increase the risks of unexpected outcomes. Implementation of the 21st Century Cures Act is opening avenues for accelerated approvals of these drugs for use in clinical trials and licensure. Although overwhelming, collaboration between regulators, industry, and research and medical communities enables the field to safely meet the needs of critically ill patients. Published by Elsevier Inc.Entities:
Keywords: Biologic drug products; Cellular therapies; HCT/Ps; Licensure requirements; PHS 351 and 361
Mesh:
Substances:
Year: 2019 PMID: 31466608 DOI: 10.1016/j.hoc.2019.05.008
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722